Kera Capital Partners Inc. Purchases Shares of 1,332 Charles River Laboratories International, Inc. (NYSE:CRL)

Kera Capital Partners Inc. acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,332 shares of the medical research company’s stock, valued at approximately $246,000.

Several other large investors also recently made changes to their positions in the company. Empirical Finance LLC boosted its holdings in Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. American Trust raised its stake in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 54 shares during the period. OLD National Bancorp IN increased its position in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after buying an additional 59 shares during the period. Fiduciary Financial Group LLC increased its holdings in Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after acquiring an additional 63 shares during the period. Finally, Pinnacle Bancorp Inc. boosted its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $163.77 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company’s fifty day moving average price is $190.64 and its 200-day moving average price is $198.42. The stock has a market cap of $8.37 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12 month low of $160.85 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.72 earnings per share. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on CRL. UBS Group reaffirmed a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Redburn Atlantic assumed coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $209.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).